MATINAS BIOPHARMA HOLDINGS, INC. Payments to Acquire Marketable Securities
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Payments to Acquire Marketable Securities of $8.44 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-09-30 was $499.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for fiscal 2024 was $8.44M.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for fiscal 2022 was $9.48M, a 59.12% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for fiscal 2021 was $23.20M, a 67.83% decline from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. payments to acquire marketable securities for fiscal 2020 was $72.11M, a 1186.31% increase from fiscal 2019.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $499.00K derived: sum of 2 quarters · filed 2026-03-31 | $8.44M 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | $499.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.44M 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | $7.94M 10-Q · filed 2025-08-14 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $6.99M derived: sum of 3 quarters · filed 2024-03-27 | $9.48M 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $6.99M derived: sum of 2 quarters · filed 2023-11-08 | $9.48M 10-Q · filed 2023-11-08 | $9.48M 10-Q · filed 2022-11-02 | $14.89M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $6.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $9.48M 10-Q · filed 2023-08-09 | $9.48M 10-Q · filed 2022-08-11 | $14.89M derived: sum of 3 quarters · filed 2023-08-09 | $25.55M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $2.49M 10-Q · filed 2023-05-10 | $2.49M 10-Q · filed 2022-05-12 | $7.90M derived: sum of 2 quarters · filed 2023-05-10 | $18.56M derived: sum of 3 quarters · filed 2023-05-10 | $21.61M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $16.07M derived: sum of 2 quarters · filed 2023-03-15 | $19.11M derived: sum of 3 quarters · filed 2023-03-15 | $23.20M 10-K · filed 2023-03-15 | $23.19M 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $10.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $13.70M derived: sum of 2 quarters · filed 2022-11-02 | $17.79M 10-Q · filed 2022-11-02 | $15.69M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $7.13M 10-Q · filed 2022-08-11 | $5.04M derived: sum of 3 quarters · filed 2022-08-11 | $11.57M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $4.08M 10-Q · filed 2022-05-12 | $1.99M derived: sum of 2 quarters · filed 2022-05-12 | $8.52M derived: sum of 3 quarters · filed 2022-05-12 | $14.98M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$2.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $4.44M derived: sum of 2 quarters · filed 2022-03-11 | $10.89M derived: sum of 3 quarters · filed 2022-03-11 | $72.11M 10-K/A · filed 2022-03-11 | ||||
| 2020-09-30 | $6.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $12.99M derived: sum of 2 quarters · filed 2021-11-08 | $74.20M 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $67.67M 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $61.21M 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $5.61M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |